



PCT # 10
11/22/02
DT05 Rec'd PCT/PTO 29 OCT 2002 89

PATENT
ATTORNEY DOCKET NO. 056291-5019

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Elaine Sophie Elizabeth STOKES, et al.

Application No.: 09/913,020 ✓

Filed: May 6, 2002

For: QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS

Commissioner for Patents
BOX PATENT APPLICATION
Washington, D.C. 20231

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

Sir:

REQUEST FOR CORRECTED FILING RECEIPT

Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

There is an error with respect to the following data which is:

☒ incorrectly entered
☐ omitted

Error In

Correct Data

☒ Inventor name


Elaine Sophie Elizabeth Stokes

Dated: October 29, 2002

MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004
(202)739-3000

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP



Donald J. Bird
Reg. No. 25,323

9901
UNITED STATES PATENT AND TRADEMARK OFFICECOMMISSIONER
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20503

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS
09/913,020	05/06/2002	1614	1860	P 282705		30

00909
PILLSBURY WINTHROP, LLP
P.O. BOX 10500
MCLEAN, VA 22102

CONFIRMATION

FILING RECEIPT



OC000000008323310

Date Mailed: 05/06/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees for search and examination check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination, Attention: Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with any changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please provide any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes your reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) *Elaine Sophie Elizabeth Stokes*

Elaine Se Stokes, Macclesfield, UNITED KINGDOM;
Darren Mckercher, Macclesfield, UNITED KINGDOM;
Laurent Fa Hennequin, Reims, FRANCE;
Patrick Ple, Reims, FRANCE;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/GB00/00373 02/08/2000

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 99400305.1 02/10/1999

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

RECEIVED

Early Publication Request: No

MAY 11 2002

Title

MORGAN LEWIS & BOCKIUS LLP

Quinazoline derivatives as angiogenesis inhibitors

Preliminary Class

56291-5
DOCKETED
By SDW Date 7-2

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).